A federal judge rebuffed Aegerion's proposed $36M marketing settlement, saying it highlights a "two-tier criminal justice system."

U.K. antitrust watchdogs are targeting Concordia and its pricing for liothyonine, a thyroid drug that now costs 57 times more than it did in 2006.

Pharma stands to prevail again in Washington, D.C., if a new Part D rule proposal from the Centers for Medicare & Medicaid Services makes its way into law.

Two of Roche's newest drugs—including the just-approved hemophilia therapy Hemlibra—racked up data that bolster their case for $1 billion-plus sales.

With all eyes fixed on Monday's vote for the European Medicines Agency relocation, Milan and Amsterdam emerged as top picks.

Biocon has resolved FDA concerns about a plant in India, setting it and Mylan up to potentially win FDA approval for the first Herceptin biosimilar.

Facing a rash of lawsuits claiming aggressive opioid marketing led to a nationwide epidemic, Purdue Pharma is reportedly initiating settlement talks.

Atopic dermatitis awareness is again at the center of a Sanofi and Regeneron skin health campaign.